Effects of serotonin 5‐HT1A agonist in advanced Parkinson's disease

@article{BaraJimenez2005EffectsOS,
  title={Effects of serotonin 5‐HT1A agonist in advanced Parkinson's disease},
  author={William Bara‐Jimenez and Francesco Bibbiani and Michael J. Morris and Tzvetelina D Dimitrova and Abdullah Sherzai and M. Maral Mouradian and Thomas Newell Chase},
  journal={Movement Disorders},
  year={2005},
  volume={20}
}
Intermittent stimulation of striatal dopaminergic receptors seems to contribute to motor dysfunction in advanced Parkinson's disease (PD). With severe dopaminergic denervation, exogenous levodopa is largely decarboxylated to dopamine in serotonergic terminals. If 5‐HT1A autoreceptors regulate dopamine as well as serotonin release, in parkinsonian patients inhibition of striatal serotonergic neuron firing might help maintain more physiological intrasynaptic dopamine concentrations and thus… Expand
5-HT1 receptor agonists for the treatment of L-DOPA-induced dyskinesia: From animal models to clinical investigation
TLDR
Pre-clinical data suggest that simultaneous activation of 5- HT1A and 5-HT1B receptors induced a potent synergistic effect on suppression of dyskinesia, which is the most problematic side effect during chronic L-DOPA treatment in parkinsonian patients. Expand
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
TLDR
It is shown that dyskinesia induced by chronic L-DOPA treatment in rats with 6-hydroxydopamine-induced lesions of the nigrostriatal dopamine pathway is critically dependent on the integrity and function of the serotonergic system. Expand
Serotonin and Parkinson's disease: On movement, mood, and madness
TLDR
An appreciation of the multiple roles that serotonin (5‐HT) may play in Parkinson's disease has increased, but several unanswered questions remain, and future studies need to focus on correlating changes in 5‐HT neurotransmission in both pathological and in vivo imaging studies with a full clinical phenotype. Expand
Serotonin transporter inhibition attenuates l‐DOPA‐induced dyskinesia without compromising l‐DOPA efficacy in hemi‐parkinsonian rats
TLDR
The present results support targeting serotonin transporters to improve Parkinson's disease treatment and provide further evidence for the role of the serotonin system in l‐DOPA’s effects. Expand
Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats
TLDR
It is demonstrated that prolonged SERT inhibition provides enduring anti-dyskinetic effects in part via 5-HT(1A) receptors while maintaining L-DOPA's anti-parkinsonian efficacy by enhancing striatal DA levels. Expand
Hypothesis: a promising effect of 5-HT1A receptor agonists in alleviating motor symptoms of Parkinson's disease.
TLDR
Augmentation of 5-HT1A agonists to anti- parkinsonian and neuroleptic drugs (D2 receptor blockers) may increase efficiency of anti-parkinsonian drugs and may also prevent motor complications induced by neuroleptic drugs. Expand
Pharmacological treatment of Parkinson’s disease: life beyond dopamine D2/D3 receptors?
TLDR
Questions and concerns are raised about the true reliability of animal studies, the adequacy of the working hypotheses and design of clinical trials, the validity of tools in current use to evaluate a particular effect, and the selectivity of the drugs used. Expand
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.
TLDR
Striatal serotonergic terminals contribute to LIDs pathophysiology via aberrant processing of exogenous levodopa and release of dopamine as false neurotransmitter in the denervated striatum of PD patients with LIDs, which supports the development of selective serotonin receptor type 1A agonists for use as antidyskinetic agents in PD. Expand
Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
TLDR
5-HT ligands can modulate basal ganglia function and hence motor function through several receptor subtypes and locations, with potential therapeutic benefit to the motor complications induced by long-term l-DOPA therapy in PD. Expand
Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson’s Disease and Adverse Effects of L-DOPA
TLDR
The role of the serotonergic system in LID is discussed and if therapeutic approaches specifically targeting this system may constitute an effective strategy in PD is discussed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models
TLDR
Drugs acting to stimulate 5-HT1A receptors could prove useful in the treatment of the motor response complications in parkinsonian patients. Expand
Quetiapine Attenuates Levodopa-Induced Motor Complications in Rodent and Primate Parkinsonian Models
TLDR
The results suggest that quetiapine could confer therapeutic benefits to patients with levodopa-induced motor complications and may indicate that 5HT2A/C receptor-mediated mechanisms, alone or in combination with other mechanisms, contribute to the pathogenesis of the altered motor responses associated with the treatment of PD. Expand
Adenosine A2A receptor antagonist treatment of Parkinson’s disease
Background: Observations in animal models suggest that A2A antagonists confer benefit by modulating dopaminergic effects on the striatal dysfunction associated with motor disability. ThisExpand
Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.
TLDR
The hypothesis that A(2A) receptor mechanisms contribute to symptom production in PD and that drugs able to selectively block these receptors may help palliate symptoms in levodopa-treated patients with this disorder is supported. Expand
Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.
TLDR
Observations that NMDA receptor antagonists injected into the striatum or given systemically have the ability to act palliatively or prophylactically to alleviate levodopa-induced response alterations support the view that sensitization of striatal NMDA receptors contributes to the pathogenesis of motor dysfunction in Parkinson's disease. Expand
Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments
  • P. Jenner
  • Psychology, Medicine
  • Journal of Neurology
  • 2000
TLDR
The mechanisms underlying the manifestations and the priming process for dyskinesia remain unknown, but non-dopaminergic approaches to therapy may provide an effective way of preventing, or limiting, the expression of involuntary movements in Parkinson's disease. Expand
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
TLDR
It is suggested that amantadine given as adjuvant to levodopa can markedly improve motor response complications and support the view that hyperfunction of NMDA receptors contributes to the pathogenesis oflevodopa-associated motor complications. Expand
Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors.
TLDR
It is hypothesize that the risk of developing motor complications in PD patients when levodopa is introduced can be reduced if the levdopa is coupled with a COMT inhibitor so as to provide more continuous dopaminergic stimulation of dopamine receptors. Expand
Glutamate Receptors and Parkinson’s Disease
TLDR
Analysis of the effects of glutamate receptor ligands in the basal ganglia circuit suggests that both ionotropic and metabotropic glutamate receptors could have antiparkinsonian actions, and NMDA receptor antagonists that selectively target the NR2B subunit and antagonists of the metabotrop glutamate receptor mGluR5 appear to hold promise and deserve future attention. Expand
Loss of bidirectional striatal synaptic plasticity in L-DOPA–induced dyskinesia
TLDR
Results indicate that abnormal information storage in corticostriatal synapses is linked with the development of L-DOPA–induced dyskinesia. Expand
...
1
2
3
4
...